GIVING HOPE TO PEOPLE IN DARKNESS
The Choroideremia Research Foundation gave me hope and a sense of community.”— Brent Rische, CRF member The Choroideremia Research Foundations Provides Education
CRF FUNDS EXPLORATORY RESEARCH PROPOSALS COMMENCING SUMMER 2020
Abigail Fahim to Study the Impact of RPE Proteins on Choroids "Understanding the relationship between RPE and choroids is vital to finding
CHOROIDEREMIA RESEARCH FOUNDATION STRENGTHENS LEADERSHIP
Four New Members Join the Board of Directors Springfield, MA., July 16, 2020 The Choroideremia Research Foundation (CRF) is pleased to announce
The Choroideremia Research Foundation Announces Funding Grants for CHM Research
The CRF awards three research grants totaling $219,000 to continue leading efforts to find a cure for Choroideremia Springfield, MA., November 25,
The Choroideremia Research Foundation Announces First Annual Randy Wheelock Research Award
Researchers may submit proposals for projects related to finding a cure for CHM by November 15, 2019 Springfield, MA., October 7, 2019
The Choroideremia Research Foundation Announces New Executive Director and Chief Medical Officer
The Choroideremia Research Foundation announced the appointment of Kathi Wagner to the position of Executive Director and Chris Moen, MD to the
Choroideremia Research Foundation Holds 2019 International Choroideremia Symposium
On June 6-7, the Choroideremia Research Foundation (CRF) hosted its 2019 International Choroideremia Symposium in Philadelphia, Pennsylvania. With the support of the
Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial
Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in
Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Study
Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75 Million which will be used to advance the company’s gene therapy